Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Main finding · VTEResult — go to the resultFully adjusted HR 1.73 95% CI 1.24–2.42Authors' conclusion
Patients with RA treated with JAKi in clinical practice are at increased risk of VTE compared with those treated with bDMARDs, an increase numerically confined to PE.
Study context
- Population
- Patients with rheumatoid arthritis (RA), Swedish Rheumatology Quality Register linked to national health registers, Sweden 2010–202132,737 treatment initiations
- Exposure
- Janus kinase inhibitors (JAKi) vs tumour necrosis factor inhibitors (TNFi) vs non-TNFi bDMARD initiators in RA; general population and overall RA cohorts for context
- Overall RAn = 85,722
- General populationn = 92,108
- Outcome
- Time to first VTE during follow-up, overall and by deep vein thrombosis (DVT) and pulmonary embolism (PE)
Methodological detailsnationwide register-based, active comparator, new user design, matched 1:5 general population cohort, Cox regression, multivariable-adjusted
- Nationwide register-based
- Active comparator
- New user design
- Matched 1:5 general population cohort
- Cox regression, multivariable-adjusted
Main finding
VTE
Fully adjusted HR
1.73
95% CI 1.24–2.42
By group
JAKivs TNFi
fully adjusted HR 1.73 (95% CI 1.24–2.42)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Fully adjusted HR (95% CI) | |
|---|---|---|
| PEJAKivs TNFi | 3.21 (2.11–4.88) | |
| DVTJAKivs TNFi | 0.83 (0.47–1.45) | |
| 0.20.5125Fully adjusted HR (log scale) |
Original publication
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. Published 23 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →